Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1-2/2013

01-06-2013

Animal models of leukemia: any closer to the real thing?

Authors: Guerry J. Cook, Timothy S. Pardee

Published in: Cancer and Metastasis Reviews | Issue 1-2/2013

Login to get access

Abstract

Animal models have been invaluable in the efforts to better understand and ultimately treat patients suffering from leukemia. While important insights have been gleaned from these models, limitations must be acknowledged. In this review, we will highlight the various animal models of leukemia and describe their contributions to the improved understanding and treatment of these cancers.
Literature
1.
Siegel, R., Ward, E., Brawley, O., & Jemal, A. (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians, 61, 212–236.CrossRef
2.
Gilliland, D.G., Jordan, C.T., Felix, C.A. (2004). The molecular basis of leukemia. Hematology/the Education Program of the American Society of Hematology, 80–97.
3.
Licht, J.D., & Sternberg, D.W. (2005). The molecular pathology of acute myeloid leukemia. Hematology/the Education Program of the American Society of Hematology, 137–142.
4.
Lowenberg, B. (2008). Acute myeloid leukemia: the challenge of capturing disease variety. Hematology / the Education Program of the American Society of Hematology, 2008, 1–11.CrossRef
5.
Dohner, H., Estey, E. H., Amadori, S., et al. (2010). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115, 453–474.PubMedCrossRef
6.
Nervi, B., Ramirez, P., Rettig, M. P., et al. (2009). Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood, 113, 6206–6214.PubMedCrossRef
7.
Jaiswal, S., Jamieson, C. H., Pang, W. W., et al. (2009). CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell, 138, 271–285.PubMedCrossRef
8.
Majeti, R., Chao, M. P., Alizadeh, A. A., et al. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell, 138, 286–299.PubMedCrossRef
9.
Colmone, A., Amorim, M., Pontier, A. L., Wang, S., Jablonski, E., & Sipkins, D. A. (2008). Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science, 322, 1861–1865.PubMedCrossRef
10.
Lapidot, T., Sirard, C., Vormoor, J., et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645–648.PubMedCrossRef
11.
Jordan, C. T., Guzman, M. L., & Noble, M. (2006). Cancer stem cells. The New England Journal of Medicine, 355, 1253–1261.PubMedCrossRef
12.
Skipper, H. E., & Perry, S. (1970). Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Research, 30, 1883–1897.PubMed
13.
Law, L. W., Taormina, V., & Boyle, P. J. (1954). Response of acute lymphocytic leukemias to the purine antagonist 6-mercaptopurine. Annals of the New York Academy of Sciences, 60, 244–250.PubMedCrossRef
14.
McCormack, E., Bruserud, O., & Gjertsen, B. T. (2005). Animal models of acute myelogenous leukaemia—development, application and future perspectives. Leukemia, 19, 687–706.PubMedCrossRef
15.
Skipper, H. E., Schabel, F. M., Jr., & Wilcox, W. S. (1967). Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemotherapy Reports, 51, 125–165.
16.
Friend, C. (1957). Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia. The Journal of Experimental Medicine, 105, 307–318.PubMedCrossRef
17.
Linemeyer, D. L., Menke, J. G., Ruscetti, S. K., Evans, L. H., & Scolnick, E. M. (1982). Envelope gene sequences which encode the gp52 protein of spleen focus-forming virus are required for the induction of erythroid cell proliferation. Journal of Virology, 43, 223–233.PubMed
18.
Wolff, L., & Ruscetti, S. (1985). Malignant transformation of erythroid cells in vivo by introduction of a nonreplicating retrovirus vector. Science, 228, 1549–1552.PubMedCrossRef
19.
Back, J., Dierich, A., Bronn, C., Kastner, P., & Chan, S. (2004). PU.1 determines the self-renewal capacity of erythroid progenitor cells. Blood, 103, 3615–3623.PubMedCrossRef
20.
Erkeland, S. J., Valkhof, M., Heijmans-Antonissen, C., et al. (2004). Large-scale identification of disease genes involved in acute myeloid leukemia. Journal of Virology, 78, 1971–1980.PubMedCrossRef
21.
Caudell, D., Harper, D. P., Novak, R. L., et al. (2010). Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. Blood, 115, 1194–1203.PubMedCrossRef
22.
Slape, C., Hartung, H., Lin, Y. W., Bies, J., Wolff, L., & Aplan, P. D. (2007). Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Research, 67, 5148–5155.PubMedCrossRef
23.
Skipper, H. E., Schabel, F. M., Jr., Trader, M. W., & Laster, W. R., Jr. (1969). Response to therapy of spontaneous, first passage, and long passage lines of AK leukemia. Cancer Chemotherapy Reports, 53, 345–366.
24.
Vassiliou, G. S., Cooper, J. L., Rad, R., et al. (2011). Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nature Genetics, 43, 470–475.PubMedCrossRef
25.
Collier, L. S., Adams, D. J., Hackett, C. S., et al. (2009). Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Research, 69, 8429–8437.PubMedCrossRef
26.
Heyer, J., Kwong, L. N., Lowe, S. W., & Chin, L. (2010). Non-germline genetically engineered mouse models for translational cancer research. Nature Reviews. Cancer, 10, 470–480.PubMedCrossRef
27.
Early, E., Moore, M. A., Kakizuka, A., et al. (1996). Transgenic expression of PML/RARalpha impairs myelopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 93, 7900–7904.PubMedCrossRef
28.
Brown, D., Kogan, S., Lagasse, E., et al. (1997). A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 94, 2551–2556.PubMedCrossRef
29.
Grisolano, J. L., Wesselschmidt, R. L., Pelicci, P. G., & Ley, T. J. (1997). Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood, 89, 376–387.PubMed
30.
He, L. Z., Guidez, F., Tribioli, C., et al. (1998). Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nature Genetics, 18, 126–135.PubMedCrossRef
31.
Zuber, J., Radtke, I., Pardee, T. S., et al. (2009). Mouse models of human AML accurately predict chemotherapy response. Genes & Development, 23, 877–889.CrossRef
32.
Grimwade, D., Walker, H., Oliver, F., et al. (1998). The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood, 92, 2322–2333.PubMed
33.
Okuda, T., Cai, Z., Yang, S., et al. (1998). Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood, 91, 3134–3143.PubMed
34.
Rhoades, K. L., Hetherington, C. J., Harakawa, N., et al. (2000). Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood, 96, 2108–2115.PubMed
35.
Yuan, Y., Zhou, L., Miyamoto, T., et al. (2001). AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proceedings of the National Academy of Sciences of the United States of America, 98, 10398–10403.PubMedCrossRef
36.
Dash, A. B., Williams, I. R., Kutok, J. L., et al. (2002). A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proceedings of the National Academy of Sciences of the United States of America, 99, 7622–7627.PubMedCrossRef
37.
Grisolano, J. L., O’Neal, J., Cain, J., & Tomasson, M. H. (2003). An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America, 100, 9506–9511.PubMedCrossRef
38.
Lavau, C., Du, C., Thirman, M., & Zeleznik-Le, N. (2000). Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO Journal, 19, 4655–4664.PubMedCrossRef
39.
Look, A. T. (1997). Oncogenic transcription factors in the human acute leukemias. Science, 278, 1059–1064.PubMedCrossRef
40.
Daser, A., & Rabbitts, T. H. (2004). Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes & Development, 18, 965–974.CrossRef
41.
Corral, J., Lavenir, I., Impey, H., et al. (1996). An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell, 85, 853–861.PubMedCrossRef
42.
Strissel, P. L., Strick, R., Tomek, R. J., Roe, B. A., Rowley, J. D., & Zeleznik-Le, N. J. (2000). DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis. Human Molecular Genetics, 9, 1671–1679.PubMedCrossRef
43.
Collins, E. C., Pannell, R., Simpson, E. M., Forster, A., & Rabbitts, T. H. (2000). Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development. EMBO Reports, 1, 127–132.PubMedCrossRef
44.
Forster, A., Pannell, R., Drynan, L. F., et al. (2003). Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell, 3, 449–458.PubMedCrossRef
45.
Stirewalt, D. L., & Radich, J. P. (2003). The role of FLT3 in haematopoietic malignancies. Nature Reviews. Cancer, 3, 650–665.PubMedCrossRef
46.
Li, L., Piloto, O., Nguyen, H. B., et al. (2008). Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood, 111, 3849–3858.PubMedCrossRef
47.
Greenblatt, S., Li, L., Slape, C., et al. (2012). Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. Blood.
48.
Chan, I. T., & Gilliland, D. G. (2004). Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia. Cell Cycle, 3, 536–537.PubMedCrossRef
49.
MacKenzie, K. L., Dolnikov, A., Millington, M., Shounan, Y., & Symonds, G. (1999). Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood, 93, 2043–2056.PubMed
50.
Martelli, A. M., Nyakern, M., Tabellini, G., et al. (2006). Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia, 20, 911–928.PubMedCrossRef
51.
Yu, H., Li, Y., Gao, C., et al. (2010). Relevant mouse model for human monocytic leukemia through Cre/lox-controlled myeloid-specific deletion of PTEN. Leukemia, 24, 1077–1080.PubMedCrossRef
52.
Cutts, B. A., Sjogren, A. K., Andersson, K. M., et al. (2009). Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice. Blood, 114, 3629–3632.PubMedCrossRef
53.
de Guzman, C. G., Warren, A. J., Zhang, Z., et al. (2002). Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Molecular and Cellular Biology, 22, 5506–5517.PubMedCrossRef
54.
Pardee, T. S., Zuber, J., & Lowe, S. W. (2011). Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. Experimental Hematology, 39, 473–485 e474.PubMedCrossRef
55.
Bruserud, O., Tore, G. B., Brustugun, O. T., et al. (1995). Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia, 9, 1910–1920.PubMed
56.
Bruserud, O., Gjertsen, B. T., & von Volkman, H. L. (2000). In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. Journal of Hematotherapy & Stem Cell Research, 9, 923–932.CrossRef
57.
Nara, N., & Miyamoto, T. (1982). Direct and serial transplantation of human acute myeloid leukaemia into nude mice. British Journal of Cancer, 45, 778–782.PubMedCrossRef
58.
Sawyers, C. L., Gishizky, M. L., Quan, S., Golde, D. W., & Witte, O. N. (1992). Propagation of human blastic myeloid leukemias in the SCID mouse. Blood, 79, 2089–2098.PubMed
59.
Ailles, L. E., Gerhard, B., Kawagoe, H., & Hogge, D. E. (1999). Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood, 94, 1761–1772.PubMed
60.
Wunderlich, M., Chou, F. S., Link, K. A., et al. (2010). AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia, 24, 1785–1788.PubMedCrossRef
61.
Svejda, J., Kossey, P., Hlavayova, E., & Svec, F. (1958). Histological picture of the transplantable rat leukaemia induced by x-irradiation and methylcholanthrene. Neoplasma, 5, 123–131.PubMed
62.
Moriuchi, T., Oikawa, T., Kodama, T., Yamaguchi, H., & Kobayashi, H. (1983). Establishment and characterization of a transplantable rat myelomonocytic leukemia. Cancer Research, 43, 5478–5483.PubMed
63.
Ivankovic, S., & Zeller, W. J. (1974). [Leukemia L 5222 of the rat strain BD IX. An ethylnitrosourea-induced monocytic-myeloic transplantable form for cytochemical and chemotherapeutic studies]. Blut, 28, 288–292.PubMedCrossRef
64.
Pearson, J. W., Chaparas, S. D., Torgersen, J. A., Perk, K., Chirigos, M. A., & Sher, N. A. (1974). The effect of drug therapy against a histologically defined rat leukemia. Cancer Research, 34, 355–361.PubMed
65.
Zeller, W. J., Ivankovic, S., & Schmahl, D. (1975). Chemotherapy of the transplantable acute leukemia L5222 in rats. Cancer Research, 35, 1168–1174.PubMed
66.
Hagenbeek, A., & Martens, A. C. (1983). Efficacy of high-dose cyclophosphamide in combination with total-body irradiation in the treatment of acute myelocytic leukemia: studies in a relevant rat model. Cancer Research, 43, 408–412.PubMed
67.
Hagenbeek, A., & Martens, A. C. (1980). The pathogenesis of a rat model for human acute myelocytic leukemia. Haematologica, 65, 293–308.PubMed
68.
van Bekkum, D. W., van Oosterom, P., & Dicke, K. A. (1976). In vitro colony formation of transplantable rat leukemias in comparison with human acute myeloid leukemia. Cancer Research, 36, 941–946.PubMed
69.
Martens, A. C., van Bekkum, D. W., & Hagenbeek, A. (1990). Minimal residual disease in leukemia: studies in an animal model for acute myelocytic leukemia (BNML). International Journal of Cell Cloning, 8, 27–38.PubMedCrossRef
70.
Pruvot, B., Jacquel, A., Droin, N., et al. (2011). Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. Haematologica, 96, 612–616.PubMedCrossRef
71.
Corkery, D. P., Dellaire, G., & Berman, J. N. (2011). Leukaemia xenotransplantation in zebrafish–chemotherapy response assay in vivo. British Journal of Haematology, 153, 786–789.PubMedCrossRef
72.
Osman, D., Gobert, V., Ponthan, F., Heidenreich, O., Haenlin, M., & Waltzer, L. (2009). A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO. Proceedings of the National Academy of Sciences of the United States of America, 106, 12043–12048.PubMedCrossRef
73.
Hunger, S.P., Lu, X., Devidas, M., et al. (2012). Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children’s Oncology Group. Journal of Clinical Oncology.
74.
Pear, W. S., Aster, J. C., Scott, M. L., et al. (1996). Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. The Journal of Experimental Medicine, 183, 2283–2291.PubMedCrossRef
75.
Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P. K., & Groffen, J. (1990). Acute leukaemia in bcr/abl transgenic mice. Nature, 344, 251–253.PubMedCrossRef
76.
Law, L. W., Dunn, T. B., et al. (1949). Observations on the effect of a folic-acid antagonist on transplantable lymphoid leukemias in mice. Journal of the National Cancer Institute, 10, 179–192.PubMed
77.
Trainer, D. L., & Wheelock, E. F. (1984). Characterization of L5178Y cell phenotypes isolated during progression of the tumor-dormant state in DBA2 mice. Cancer Research, 44, 2897–2906.PubMed
78.
Nishimura, T., Muto, K., & Tanaka, N. (1978). Drug sensitivity of an adriamycin-resistant mutant subline of mouse lymphoblastoma L5178Y cells. Journal of Antibiotics (Tokyo), 31, 493–495.CrossRef
79.
Nishimura, T., Suzuki, H., Muto, K., & Tanaka, N. (1979). Mechanism of adriamycin resistance in a subline of mouse lymphoblastoma L5178Y cells. Journal of Antibiotics (Tokyo), 32, 518–522.CrossRef
80.
Cloyd, M. W., Hartley, J. W., & Rowe, W. P. (1980). Lymphomagenicity of recombinant mink cell focus-inducing murine leukemia viruses. The Journal of Experimental Medicine, 151, 542–552.PubMedCrossRef
81.
Yun, J. P., Behan, J. W., Heisterkamp, N., et al. (2010). Diet-induced obesity accelerates acute lymphoblastic leukemia progression in two murine models. Cancer Prevention Research (Philadelphia, Pa.), 3, 1259–1264.CrossRef
82.
Weiser, K. C., Liu, B., Hansen, G. M., et al. (2007). Retroviral insertions in the VISION database identify molecular pathways in mouse lymphoid leukemia and lymphoma. Mammalian Genome, 18, 709–722.PubMedCrossRef
83.
Dettman, E. J., Simko, S. J., Ayanga, B., et al. (2011). Prdm14 initiates lymphoblastic leukemia after expanding a population of cells resembling common lymphoid progenitors. Oncogene, 30, 2859–2873.PubMedCrossRef
84.
Groffen, J., Voncken, J. W., Kaartinen, V., Morris, C., & Heisterkamp, N. (1993). Ph-positive leukemia: a transgenic mouse model. Leukemia & Lymphoma, 11(Suppl 1), 19–24.CrossRef
85.
Reichert, A., Heisterkamp, N., Daley, G. Q., & Groffen, J. (2001). Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood, 97, 1399–1403.PubMedCrossRef
86.
Kaur, P., Feldhahn, N., Zhang, B., et al. (2007). Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Molecular Cancer, 6, 67.PubMedCrossRef
87.
Chen, W., Li, Q., Hudson, W. A., Kumar, A., Kirchhof, N., & Kersey, J. H. (2006). A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood, 108, 669–677.PubMedCrossRef
88.
Metzler, M., Forster, A., Pannell, R., et al. (2006). A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene, 25, 3093–3103.PubMedCrossRef
89.
Tamai, H., Miyake, K., Takatori, M., et al. (2011). Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. Leukemia, 25, 888–891.PubMedCrossRef
90.
Harris, A. W., Pinkert, C. A., Crawford, M., Langdon, W. Y., Brinster, R. L., & Adams, J. M. (1988). The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. The Journal of Experimental Medicine, 167, 353–371.PubMedCrossRef
91.
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W. (1999). INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes & Development, 13, 2670–2677.CrossRef
92.
Schmitt, C. A., Fridman, J. S., Yang, M., et al. (2002). A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell, 109, 335–346.PubMedCrossRef
93.
Grabher, C., von Boehmer, H., & Look, A. T. (2006). Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nature Reviews. Cancer, 6, 347–359.PubMedCrossRef
94.
Ellisen, L. W., Bird, J., West, D. C., et al. (1991). TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell, 66, 649–661.PubMedCrossRef
95.
Weng, A. P., Ferrando, A. A., Lee, W., et al. (2004). Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science, 306, 269–271.PubMedCrossRef
96.
Deftos, M. L., Huang, E., Ojala, E. W., Forbush, K. A., & Bevan, M. J. (2000). Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. Immunity, 13, 73–84.PubMedCrossRef
97.
Fowlkes, B. J., & Robey, E. A. (2002). A reassessment of the effect of activated Notch1 on CD4 and CD8 T cell development. Journal of Immunology, 169, 1817–1821.
98.
Priceputu, E., Bouallaga, I., Zhang, Y., et al. (2006). Structurally distinct ligand-binding or ligand-independent Notch1 mutants are leukemogenic but affect thymocyte development, apoptosis, and metastasis differently. Journal of Immunology, 177, 2153–2166.
99.
Berquam-Vrieze, K. E., Swing, D. A., Tessarollo, L., & Dupuy, A. J. (2012). Characterization of transgenic mice expressing cancer-associated variants of human NOTCH1. Genesis, 50, 112–118.PubMedCrossRef
100.
Boulos, N., Mulder, H. L., Calabrese, C. R., et al. (2011). Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 117, 3585–3595.PubMedCrossRef
101.
Duy, C., Hurtz, C., Shojaee, S., et al. (2011). BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature, 473, 384–388.PubMedCrossRef
102.
Wang, P. Y., Young, F., Chen, C. Y., et al. (2008). The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. Blood, 112, 4184–4192.PubMedCrossRef
103.
Barabe, F., Kennedy, J. A., Hope, K. J., & Dick, J. E. (2007). Modeling the initiation and progression of human acute leukemia in mice. Science, 316, 600–604.PubMedCrossRef
104.
Wei, J., Wunderlich, M., Fox, C., et al. (2008). Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell, 13, 483–495.PubMedCrossRef
105.
le Viseur, C., Hotfilder, M., Bomken, S., et al. (2008). In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell, 14, 47–58.PubMedCrossRef
106.
Chiu, P. P., Jiang, H., & Dick, J. E. (2010). Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood, 116, 5268–5279.PubMedCrossRef
107.
Otova, B., Sladka, M., Panczak, A., & Marinov, I. (1997). Biological characteristics of spontaneous transplantable T-cell lymphomas in inbred Sprague–Dawley/Cub rats. Transplantation Proceedings, 29, 1754–1755.PubMedCrossRef
108.
Otova, B., Vaclavikova, R., Danielova, V., et al. (2006). Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague–Dawley/Cub rats. European Journal of Pharmaceutical Sciences, 29, 442–450.PubMedCrossRef
109.
Congdon, C. C., & Lorenz, E. (1954). Leukemia in guinea-pigs. American Journal of Pathology, 30, 337–359.PubMed
110.
Sabaawy, H. E., Azuma, M., Embree, L. J., Tsai, H. J., Starost, M. F., & Hickstein, D. D. (2006). TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 103, 15166–15171.PubMedCrossRef
111.
Frazer, J. K., Meeker, N. D., Rudner, L., et al. (2009). Heritable T-cell malignancy models established in a zebrafish phenotypic screen. Leukemia, 23, 1825–1835.PubMedCrossRef
112.
Langenau, D. M., Traver, D., Ferrando, A. A., et al. (2003). Myc-induced T cell leukemia in transgenic zebrafish. Science, 299, 887–890.PubMedCrossRef
113.
Feng, H., Langenau, D. M., Madge, J. A., et al. (2007). Heat-shock induction of T-cell lymphoma/leukaemia in conditional Cre/lox-regulated transgenic zebrafish. British Journal of Haematology, 138, 169–175.PubMedCrossRef
114.
Feng, H., Stachura, D. L., White, R. M., et al. (2010). T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell, 18, 353–366.PubMedCrossRef
115.
Nowell, P. C., & Hungerford, D. A. (1962). Chromosome studies in human leukemia. IV. Myeloproliferative syndrome and other atypical myeloid disorders. Journal of the National Cancer Institute, 29, 911–931.PubMed
116.
Goldman, J.M., (2009). Initial treatment for patients with CML. Hematology/the Education Program of the American Society of Hematology, 453–460.
117.
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990). Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science, 247, 824–830.PubMedCrossRef
118.
Li, S., Ilaria, R. L., Jr., Million, R. P., Daley, G. Q., & Van Etten, R. A. (1999). The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. The Journal of Experimental Medicine, 189, 1399–1412.PubMedCrossRef
119.
Zhang, H., Li, H., Xi, H. S., & Li, S. (2012). HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells. Blood, 119, 2595–2607.PubMedCrossRef
120.
Huettner, C. S., Koschmieder, S., Iwasaki, H., et al. (2003). Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood, 102, 3363–3370.PubMedCrossRef
121.
Huettner, C. S., Zhang, P., Van Etten, R. A., & Tenen, D. G. (2000). Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genetics, 24, 57–60.PubMedCrossRef
122.
Chu, S., McDonald, T., Lin, A., et al. (2011). Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood, 118, 5565–5572.PubMedCrossRef
123.
Lozzio, B. B., Lozzi, C. B., & Machado, E. (1976). Human myelogenous (Ph+) leukemia cell line: transplantation into athymic mice. Journal of the National Cancer Institute, 56, 627–629.PubMed
124.
Skorski, T., Nieborowska-Skorska, M., Nicolaides, N. C., et al. (1994). Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proceedings of the National Academy of Sciences of the United States of America, 91, 4504–4508.PubMedCrossRef
125.
Dazzi, F., Hasserjian, R., Gordon, M. Y., et al. (2000). Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation. The Hematology Journal, 1, 307–315.PubMedCrossRef
126.
Dohner, H., Stilgenbauer, S., Benner, A., et al. (2000). Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine, 343, 1910–1916.PubMedCrossRef
127.
Phillips, J. A., Mehta, K., Fernandez, C., & Raveche, E. S. (1992). The NZB mouse as a model for chronic lymphocytic leukemia. Cancer Research, 52, 437–443.PubMed
128.
Raveche, E. S., Salerno, E., Scaglione, B. J., et al. (2007). Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood, 109, 5079–5086.PubMedCrossRef
129.
Narducci, M. G., Pescarmona, E., Lazzeri, C., et al. (2000). Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Research, 60, 2095–2100.PubMed
130.
Bichi, R., Shinton, S. A., Martin, E. S., et al. (2002). Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proceedings of the National Academy of Sciences of the United States of America, 99, 6955–6960.PubMedCrossRef
131.
Aguilar-Santelises, M., Rottenberg, M. E., Lewin, N., Mellstedt, H., & Jondal, M. (1996). Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. International Journal of Cancer, 69, 114–119.CrossRef
132.
Munzert, G., Kirchner, D., Stobbe, H., et al. (2002). Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood, 100, 3749–3756.PubMedCrossRef
133.
Zapata, J. M., Krajewska, M., Morse, H. C., 3rd, Choi, Y., & Reed, J. C. (2004). TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 101, 16600–16605.PubMedCrossRef
134.
Mohammad, R. M., Mohamed, A. N., Hamdan, M. Y., et al. (1996). Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia, 10, 130–137.PubMed
135.
Mohammad, R. M., Limvarapuss, C., Hamdy, N., et al. (1999). Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. International Journal of Oncology, 14, 945–950.PubMed
136.
Loisel, S., Ster, K. L., Quintin-Roue, I., et al. (2005). Establishment of a novel human B-CLL-like xenograft model in nude mouse. Leukemia Research, 29, 1347–1352.PubMedCrossRef
137.
Durig, J., Ebeling, P., Grabellus, F., et al. (2007). A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Research, 67, 8653–8661.PubMedCrossRef
138.
Aydin, S., Grabellus, F., Eisele, L., et al. (2011). Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model. European Journal of Haematology, 87, 10–19.PubMedCrossRef
Metadata
Title
Animal models of leukemia: any closer to the real thing?
Authors
Guerry J. Cook
Timothy S. Pardee
Publication date
01-06-2013
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1-2/2013
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9405-5

Other articles of this Issue 1-2/2013

Cancer and Metastasis Reviews 1-2/2013 Go to the issue

NON-THEMATIC REVIEW

Stromal cells in tumor microenvironment and breast cancer

OriginalPaper

Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis

NON-THEMATIC REVIEW

The role of the tissue omega-6/omega-3 fatty acid ratio in regulating tumor angiogenesis

OriginalPaper

Reconstructing skin cancers using animal models

NON-THEMATIC REVIEW

Tumor dormancy and the neuroendocrine system: an undisclosed connection?

OriginalPaper

What underlies the diversity of brain tumors?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits